Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.65 |
| ▸ | MAPT | P10636 | 4/20 | 0.63 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.49 |
| ▸ | THRA | P10827 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21829010 | 0.98 | MAPT (0.63) | MEN1KMT2AMAPTTSHRL3MBTL1 | |
| SCHEMBL21828998 | 0.84 | MEN1 (0.69) | MEN1KMT2AMAPTTSHRL3MBTL1 | |
| SCHEMBL21829017 | 0.82 | MAPT (0.67) | MEN1KMT2AMAPTALDH1A1KDM4E | |
| SCHEMBL21829011 | 0.82 | MEN1 (0.65) | MEN1KMT2AMAPTTSHRL3MBTL1 | |
| SCHEMBL21829008 | 0.80 | MAPT (0.67) | MEN1KMT2AMAPTTSHRALDH1A1 | |
| SCHEMBL21829001 | 0.79 | MAPT (0.70) | MEN1KMT2AMAPTALDH1A1KDM4E | |
| SCHEMBL28506638 | 0.79 | MEN1 (0.65) | MEN1KMT2AMAPTTSHRL3MBTL1 | |
| SCHEMBL12218573 | 0.79 | MEN1 (1.00) | MEN1KMT2AMAPTTSHRL3MBTL1 | |
| SCHEMBL21829009 | 0.78 | MAPT (0.68) | MEN1KMT2AMAPTTSHRALDH1A1 | |
| SCHEMBL21829016 | 0.77 | MAPT (0.67) | MEN1KMT2AMAPTALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020072492-A1 | BENZAMIDE DERIVATIVES AS CGAS-STING PATHWAY AGONISTS | BARUCH S. BLUMBERG INSTITUTE (US) | 2020-04-09 | — | — | WO | claimed |
| US-20210347752-A1 | BENZAMIDE DERIVATIVES AS CGAS-STING PATHWAY AGONISTS | BARUCH S. BLUMBERG INSTITUTE | 2021-11-11 | — | — | US | disclosed |
| WO-2020072492-A1 | BENZAMIDE DERIVATIVES AS CGAS-STING PATHWAY AGONISTS | BARUCH S. BLUMBERG INSTITUTE (US) | 2020-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210347752-A1 | BENZAMIDE DERIVATIVES AS CGAS-STING PATHWAY AGONISTS | STING1, CGAS, MAVS | MEN1 4179/4885KMT2A 2676/4885MAPT 4381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.